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Abstract
Objective: Invasive pneumococcal disease (IPD) primarily affects children less than 5 years old, the elderly and
certain at-risk groups; especially people infected by the human immunodeficiency virus (HIV). The objective of this
study was to analyze invasive pneumococcal diseases (IPD) in children and adolescents infected by the human
immunodeficiencyvirus (HIV),with relation tomorbidity, the case fatality ratio, pneumococcus serotypes, susceptibility
to penicillin and ceftriaxone and to the proportion of susceptible and resistantStreptococcus pneumoniae (Sp) included
in the 7-valent pneumococcal conjugate vaccine that has already been licensed.
Methods:A total of 19 cases of IPDwere identified amongHIV seropositive patients aged from1month to 20 years
and hospitalized between 1993 and 2000. Data were recorded on standardized charts containing information on age,
clinical diagnosis andprogression, serotypesand thesusceptibility topenicillin andceftriaxoneof theSpstrains identified
in cultures.When theminimum inhibitory concentrationwas<0.1mcg/mL, Spwere defined as susceptible to penicillin
(SpSPn), and all other strains were defined as not susceptible (SpNSPn).
Results:Of the 19HIV seropositive caseswith IPD, 16 (84%)hadpneumonia and three (16%), hadmeningitis; 13
(68%) cases were children less than 2 years old and 16 (84%) were less than 5 years old. The case fatality ratio was
10%. Seven (54%) of the 13 cases less than 2 years oldwere SpNSPn and 10 (77%)were caused by serotypes covered
by the 7-valent pneumococcal conjugate vaccine. From the 10 isolated serotypes the most frequent were 14, 6B and
23F, all them susceptible to ceftriaxone. From the three patients with meningitis, two were caused by SpNSPn.
Conclusion: In this studymost of the IPD occurred in children less than 2 years old; 77%of the strains and 86%of
the serotypes of SpNSPn were covered by the 7-valent pneumococcal conjugate vaccine.
J Pediatr (Rio J). 2008;84(3):276-280: Pneumococcus, Streptococcus pneumoniae, children, adolescents, HIV seropositive,
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Introduction
Streptococcus pneumoniae (Sp) is one of the main etio-
logic agents of community acquired pneumonia, meningitis,
sinusitis, acute otitis media and bacteremia. Invasive pneu-
mococcal disease (IPD) primarily affects children less than 5
years old, the elderly and certain other risk groups, among
whom those infected by the human immunodeficiency virus
(HIV+) are prominent.1-4 The risk of HIV+ patients develop-
ing pneumonia is 10 to 100 times greater than for the unin-
fected.1 In Brazil, althoughHIV infection is one of the primary
risk factors for IPD, studies of IPD in this group of patients
remain scarce. We were unable to identify studies published
up to August of 2007 that provided information on Sp sero-
type identification in HIV+ children with IPD and the corre-
sponding profile of susceptibility to penicillin and ceftriaxone.
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Theavailability of newconjugate vaccines5 for thepreven-
tion of IPD in children less than 5 years old, together with the
increased prevalence of IPD caused by resistant strains, have
increased interest in identifying the main serotypes causing
this entity and their resistance profiles.
Based on the reasons explained above, our goals were:
1) to describe the cases of IPD by Sp in HIV+ children and
adolescents, analyzing morbidity, the case fatality ratio, Sp
serotypes identified and their profiles of susceptibility to peni-
cillin and ceftriaxone, broken down by age group and IPD
topography; 2) to analyze the possible spectrum of coverage
against IPD in children less than 5 years old offered by the
7-valent pneumococcal conjugate vaccine (7vPCV).
Methods
This research was carried out at the Instituto de Infecto-
loigia Emílio Ribas (IIER), which is a public hospital providing
specialist care for patients with infectious diseases andwhich
treats HIV+ individuals. Since 1993, records have been kept
of all strains of Sp isolated from cultures of normally sterile
clinicalmaterial (blood, cerebrospinal fluid, pleural fluid) from
hospitalized patients, and IPD cases were identified from
these records. Since HIV+ patients are referred to this hospi-
tal for treatment, both investigation of risk factors and sero-
logical tests forHIV investigationarepart of routine care.Once
themedical records of patientswith positiveSp cultures taken
between June 1993 and December 2000 had been identified,
themedical records of all HIV+ individuals with IPD and ages
of 1 month to 20 years were selected for this study.
The clinical progress of the patients was analyzed by
means of a systematic review of theirmedical records using a
standardized assessment protocol, covering the following
variables: age, primary and secondary diagnoses, the Sp
serotypes isolated from cultureswith their respective profiles
of resistance to penicillin and ceftriaxone and patient
progress.
The techniques employed for the identification and sero-
typing of bacteria, plus the tests for susceptibility and mini-
mum inhibitory concentration (MIC), followed the system
defined for the SIREVA Project and were all carried out at the
Instituto Adolfo Lutz in São Paulo, Brazil.6-8 Strains were
defined as susceptible to penicillin (SpSPn) and/or ceftriax-
onewhen their MICwas< 0.1mcg/mL. Strains with interme-
diate sensitivity (MIC between 0.1 and 1 mcg/mL) and with
full resistance (MIC≥ 2mcg/mL) to penicillin were defined as
not susceptible (SpNSPn).8,9
Data were recorded on standardized charts containing all
relevant information and were stored andmanipulated using
Microsoft Office Excel 2003®.
This study was approved by the Research Ethics Commit-
tee at the IIER.
Results
During the study period, 19 children and adolescentswith
IPD confirmed by culture were identified, 16 (84%) of whom
were less than 5 years old; 16 (84%) of the 19 patients had
pneumonia and three (16%), had meningitis (Table 1). None
of these patients had been vaccinated against Sp.
The serotypes isolated are listed in Table 2, according to
the susceptibility of each Sp to penicillin, with the most fre-
quent serotypebeing14 (21%), followedby6Band23F (16%
each).
Almost half of the strains isolated (47%) proved to be
SpNSPn. Children less than 2 years old (seven out of 13)
exhibited a higher rate of infection by SpNSPn (54%) com-
pared with children over 2 years. All of the strains isolated
were susceptible to ceftriaxone.
The case fatality ratio was 10.5%, with a total of two
deaths: one child with meningitis and another with pneumo-
nia and co-infectionbypulmonary tuberculosis, both less than
2 years of age.
Twelve of the 16 children less than 5 years old had IPD
caused by serotypes included in the 7vPCV (75%).
As the results show, we found 19 cases of children and
adolescents infected by HIV who also had IPD, which was not
a surprise, even over the extended period, since the number
of infected children is always much lower than the number of
HIV+ adults.
Young age is an important risk factor for IPD. In this study,
more than90%of the IPDwere identified in children less than
5 years old, and almost 80% in children less than 2 years of
age.
Themajority of studies that have been published in Brazil
mention Sp serotypes without specifying whether or not the
individual concerned was infected with HIV. The majority of
these refer to colonization of the airways by Sp, since the dif-
ficulties in isolating the bacteria from cultures from people
with pneumonia are well known.4,9-13 The only study pub-
lished in Brazil on Sp serotypes identified from HIV+ children
demonstrated that nasopharyngeal colonization of 112 chil-
dren was no greater than that described in the literature for
healthy children.3
In our study, serotype 14 was the most frequent (four
cases) andwasalso the serotype that exhibitedgreatest resis-
tance to penicillin, which confirms data published in Brazilian
literature.6,8 Three of these cases were SpNSPn in children
less than 2 years old; the other was identified in a child aged
between 2 and 5 years (Table 1).
Analysis of bacterial resistance revealed that almost half
of the IPD (47%)had been caused bySpNSPn and that, of the
10 serotypes identified, five (50%) were SpNSPn. Several
studies undertaken in different parts of Brazil have revealed
that the prevalence of SpNSPn is highly variable (15 to
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Table1 -DistributionofStreptococcuspneumoniae serotypes isolated fromHIV-positive childrenandadolescents andwith invasivepneumococcal
infections by age group, clinical diagnosis and susceptibility to penicillin
Age group
Meningitis
(Sp serotypes)
Pneumonia
(Sp serotypes)
1 month to 2 years 6B (S)* 4 (S)*
23F (NS) 9V (S)*
14† (NS) 9N (S)*
- 19A (S)*
- 19F (S)*†
- 6B (NS)
- 14 (NS)
- 14 (NS)
- 19A (NS)
- 23F (NS)
2 to 5 years 0 14 (S)*
- 6B (S)*
- 5 (S)*
5 to 10 years 0 19F (S)*
- 8 (NS)
10 to 20 years 0 23F (NS)
Total strains
(S)* vs. (NS) 1 (S)* vs. 2 (NS) 9 (S)* vs. 6 (NS)
NS = not susceptible (MIC ≥ 0.1 μg/mL); S = susceptible.
* Strains susceptible to penicillin (MIC < 0.1 μg/mL).
† Patient died.
Table 2 - Most commonStreptococcus pneumoniae serotypes isolated from HIV positive patients
Serotypes Cases
Susceptibility to penicillin
Susceptible Not susceptible
14* 4 1 3
6B* 3 2 1
23F* 3 - 3
19A 2 1 1
19F* 2 2 -
4* 1 1 -
9N 1 1 -
5 1 1 -
8 1 - 1
9V* 1 1 -
Total 19 10 9
* Serotypes included in the 7-valent pneumococcal conjugate vaccine.
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50%).8,4,10-12 Of this study, seven (54%) of the 13 children
less than 2 years old had suffered IPD due to SpNSPn. It is
possible that this high level of penicillin resistance is partially
due to the fact that HIV+ patients are often given antimicro-
bial treatment.
The identification of a high proportion of SpNSPn strains
in this sample providesmore evidence to support prescribing
ceftriaxone in suspected IPD cases among HIV+ patients at
our service. Of the 13 children less than 2 years old, and of
the 16 children less than 5 years old, 10 (77%) and 12 (75%)
respectively had IPD caused by Sp serotypes covered by the
7vPCV.
Discussion
It has beendemonstrated that the7vPCVoffersmore than
90% efficacy for the prevention of IPD caused by serotypes
that are included in it, and also for the prevention of pneumo-
nia diagnosed by X ray, in children less than 2 years old,14
following a clear decline in the incidence of IPD in the United
States, after systematic introduction of the 7vPCV for young
infants.2
Both the7vPCVandother conjugate vaccines haveproven
highly effective for the prevention of IPD in healthy people or
those infected with HIV.5,15 It is therefore essential to know
which Sp serotypes are prevalent at each healthcare pro-
vider, in order to be able to analyze the spectrum of coverage
offered by each of the new conjugate vaccines.
In this study, we identified two cases of IPD caused by
serotype 19A, which is currently considered one of the most
important in the United States, after the introduction of the
conjugate vaccine.2Bothwere isolated fromchildren less than
2 years old and, although the 7vPCV contains the 19F sero-
type, this does not provide cross protection for 19A. Serotype
19A is included in 13vVPC, which includes the serotypes 1, 3,
5 (one case was identified here), 6A, 7F and 19A, in addition
to those already in the 7vPCV. The 13vVPC could potentially
offer protection against 89.5% of the strains of Sp isolated
from Brazilian children and adolescents infected by HIV.5
Another vaccine that is available on the Brazilian market
for administration to children over 2 years old is the polysac-
charide vaccine (non-conjugate) with 23 Sp serotypes
(23vPPV).
We only identified six children older than 2 years whose
Sp serotypeswere included in the 23vPPV. Furthermore, even
children older than 2 years who have HIV infections and were
vaccinated with the 23vPPV did not respond well to the
polysaccharide antigen, when compared with controls.16
Just six children weremore than 2 years old at the time of
data collection and none of them had been given the 23vPPV,
already available at that time, confirming the published data
that states that selective vaccinationof high-riskgroups is less
efficient than vaccination of all children.
Attempting to relate clinical diagnoses, serotypes and the
profile of pneumococcus susceptibility to penicillin, the three
cases ofmeningitis were caused by Sp serotypes 6B, 23F and
14, two of which were resistant to penicillin (67%) and all of
which are covered by the 7vPCV.
In contrast with serotypes 1 and 5, which are rarely resis-
tant to penicillin, serotype 19A is becoming highly resistant.
It is interesting to note that, in our study, one of the two cases
of IPD caused by serotype 19A was SpNSPn.
In conclusion, our study has shown that a majority of IPD
in HIV+ children and adolescents affected those less than 5
years old. The prevalence of SpNSPn was very high (47%).
Six serotypes, responsible for 14 strains isolated from
72% of the 19 patients, are covered by the 7vPCV. Serotypes
covered by the 7vPCV were responsible for 75% of all sero-
types isolated and for 86% of the SpNSPn serotypes identi-
fied in cultures from children less than 5 years old, i.e. they
were cases of IPD that could have been avoided if these chil-
dren had been given the 7vPCV.
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